From an interview published in Seeking Alpha.
Dr. Kim: Can the VGX-3100 data justify a share price in the double-digits? I gave up trying to forecast a specific share price many years ago. But here is the way I see it. The data we are looking forward to from VGX-3100 is not just about efficacy data for cervical dysplasia. Positive dysplasia data could bode well for our clinical studies for inoperable cervical cancer and head/neck cancer. Together, these indications may justify a much higher valuation.
However, equally importantly, industry players and smart investors are anticipating this data in order to hopefully see not only efficacy, but a confirmation of our best-in-class T-cell data in this much larger controlled study. If this immune response data is good, then irrespective of what the efficacy data looks like, many will be convinced that our active immunotherapy combined with an immune activator, a checkpoint inhibitor, and/or some other complementary therapeutic approach will represent a unique treatment modality with tremendous potential.
I believe that perspective is what could cause investors to attach a higher valuation to Inovio.
AJ adds: What Dr Kim is saying that an effective cancer therapy via immunology may require several agents, so even if one treatment is insufficient to do the job, it might work in combination with other things. Thus, it can be income producing even if it alone does not cure cancer.
Here is a list of definitions how some immunotherapy is thought to work:
The results of the VGX-3100 study will be available in mid 2014.
No comments:
Post a Comment